Jade Biosciences, Inc. JBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | ||
|---|---|---|---|---|---|
| Net Income | -73.54% | -5.76% | -49.26% | -49.26% | |
| Total Depreciation and Amortization | 80.00% | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 30.83% | -61.09% | 137.64% | 137.64% | |
| Change in Net Operating Assets | -164.27% | 490.77% | -112.77% | -112.77% | |
| Cash from Operations | -116.56% | -28.38% | -225.26% | -225.26% | |
| Capital Expenditure | -- | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -71,688.24% | -- | -- | -- | |
| Total Debt Issued | -- | -- | -115.31% | -115.31% | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -- | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 100.00% | -20.00% | 6,480.70% | 6,480.70% | |
| Cash from Financing | 1.16% | -13.57% | -100.00% | -100.00% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -69.50% | -71.42% | -294.20% | -294.20% | |